EMA Application withdrawn: Dazluma — Biohaven Bioscience Ireland Limited

View source ↗

Summary

The EMA has withdrawn the application for Dazluma for spinocerebellar ataxias.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinocerebellar Ataxia

Drugs mentioned

• Dazluma

Snippet

Status: Application withdrawn. Therapeutic area: Spinocerebellar Ataxias. MAH: Biohaven Bioscience Ireland Limited